ESR1 and breast carcinoma: In this study, we investigated the effects of the combination of RM and DOX in estrogen receptor positive (ER+) MCF-7, an in vitro model for the most common type of breast cancer and determined the drug ratio and regimen that will yield a synergistic effect.